TORONTO, ONTARIO — (February 27, 2015) — Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results today for the fiscal quarter ended December 31, 2014. The Corporation’s unaudited Q3 2015 financial statements and MD&A are available on SEDAR.
The Company also announced that Jonathan Ross Goodman has resigned from the Company’s Board of Directors, effective today. Mr. Goodman has been a Director since June 2013. Samira Sakhia will replace Mr. Goodman as chair of the Audit Committee.
Mr. Goodman stated, “It has been a pleasure working with Antibe’s management and Board; they are an extremely talented group. My duties at Knight Therapeutics are simply too great to continue these additional responsibilities. I look forward to remaining connected with the team.”
“Antibe’s management and shareholders would like to thank Jonathan for his contributions to the company, the Board, and its shareholders. We look forward to maintaining a close working relationship with Jonathan and his business enterprises, and are grateful that he has offered continued assistance.” said Walt Macnee, Chairman of Antibe’s Board of Directors.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
dan.legault@antibethera.com
Read all news